These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11545577)

  • 1. Asymptomatic HIV patient with cardiomyopathy and nephropathy: case report and literature review.
    Tayal SC; Ghosh SK; Reaich D
    J Infect; 2001 May; 42(4):288-90. PubMed ID: 11545577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus-1 associated nephropathy (HIVAN): epidemiology, pathogenesis, histology, diagnosis, and medical management.
    Lochner ML; Wolf A
    Nephrol Nurs J; 2006; 33(3):259-67; quiz 268-9. PubMed ID: 16859198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of hepatitis C in a patient with advanced AIDS and decompensated cirrhosis.
    Johanson FD; Balliram DB
    AIDS Read; 2003 Oct; 13(10):494-6, 500-1. PubMed ID: 14596227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
    Gandhi T; Wei W; Amin K; Kazanjian P
    Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy.
    Kesselring A; Gras L; Smit C; van Twillert G; Verbon A; de Wolf F; Reiss P; Wit F
    Clin Infect Dis; 2011 Jun; 52(12):1458-65. PubMed ID: 21628488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
    Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
    Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C; Lee S; Wong Kh; Cheng L; Lam M
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antiviral therapy: when to begin, which goals should be set, what must be kept in mind? Tips for nonspecialists].
    Jablonowski H
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():10-1. PubMed ID: 16385862
    [No Abstract]   [Full Text] [Related]  

  • 14. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
    HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
    Olsen CH; Gatell J; Ledergerber B; Katlama C; Friis-Møller N; Weber J; Horban A; Staszewski S; Lundgren JD; Phillips AN;
    AIDS; 2005 Feb; 19(3):319-30. PubMed ID: 15718843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resolution of renal failure after initiation of HAART: 3 cases and a discussion of the literature.
    Kirchner JT
    AIDS Read; 2002 Mar; 12(3):103-5, 110-2. PubMed ID: 11966239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiation of antiretroviral therapy: implications of recent findings.
    Saag MS
    Top HIV Med; 2004; 12(3):83-8. PubMed ID: 15310939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study.
    Mocroft A; Phillips AN; Friis-Møller N; Colebunders R; Johnson AM; Hirschel B; Saint-Marc T; Staub T; Clotet B; Lundgren JD;
    Antivir Ther; 2002 Mar; 7(1):21-30. PubMed ID: 12008784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV therapeutics, continued: another HIV protease inhibitor approved.
    Laurence J
    AIDS Read; 2003 Aug; 13(8):355-6. PubMed ID: 14524318
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.